Featured Research

from universities, journals, and other organizations

Metformin Increases Pathologic Complete Response Rates In Breast Cancer Patients With Diabetes

Date:
June 2, 2008
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers.

Metformin, the common first-line drug for type 2 diabetes, may be effective in increasing pathologic complete response rates in diabetic women with early stage breast cancer who took the drug during chemotherapy prior to having surgery, paving the way for further research of the drug as a potential cancer therapy, according to researchers at The University of Texas M. D. Anderson Cancer Center.

The retrospective study is the first clinical research observation of the diabetes drug as a potential anti-tumor agent. The findings will be presented in a poster discussion session at the annual meeting at the American Society of Clinical Oncology (ASCO) by Sao Jirlerspong, M.D., Ph.D., a fellow, and Ana M. Gonzalez-Angulo, M.D., assistant professor, both in M. D. Anderson's Department of Breast Medical Oncology.

Metformin, an oral medication, is the most common drug prescribed for type 2 diabetes; according to Gonzalez-Angulo, more than 35 million prescription of the drug are filled annually. It's most often given to diabetic patients who are obese or have insulin resistance.

The authors decided to conduct the research after a large, intriguing epidemiologic study published last year showed that patients with diabetes who took metformin had lower incidences of cancer as well as better outcomes.

"Metformin has a novel mechanism of action. There have been a number of papers published recently that describe its action through activation of the AMP kinase pathway, which is a cellular energy sensor of the cells and potentially important pathway for the development of cancer," said Jiralerspong.

"The other interesting aspect is that Metformin works by decreasing the amount of insulin- resistance in diabetics and insulin seems to be a growth factor for cancer," said Gonzalez-Angulo.

Using the M. D. Anderson Breast Medical Oncology database, Gonzalez-Angulo, Jiralerspong and their team identified 2,529 women with early-stage breast cancer who received chemotherapy in the neoadjuvant setting, before surgery. Of the patients, 2,374 were non-diabetic, 68 were diabetic but not taking metaformin and 87 were diabetic and taking the drug. The study's endpoint was pathologic complete response, or the absence of cancer at the time of surgery.

The researchers found that the pathologic complete response rates in the diabetic breast cancer patients taking Metformin was 24 percent, three times higher than the rates in diabetic patients not taking the drug, 8 percent. In the non-diabetic women, the pathologic complete response rate was 16 percent. After adjusting for other factors, the researchers found that metformin was an independent predictor of pathologic complete response in diabetic patients.

While very exciting, the findings are still very early, cautioned Jiralerspong and Gonzalez-Angulo, and further investigation with metformin is needed.

"We need to study the mechanism of the drug - perhaps it's the decrease in insulin levels, or it may be that the drug has an anti-tumor effect that we to look at in vivo," said Gonzalez-Angulo. "Our next step is to conduct a number correlative studies to try and further understand its mechanism."

M. D. Anderson also plans to open a clinical trial with metformin in combination with hormonal therapy for metastatic breast cancer patients who are obese. The study will be led by Francisco Esteva, M.D., Ph.D., associate professor in the Department of Breast Medical Oncology.

In addition to Gonzalez-Angulo and Jiralerspong, other authors of the all-M. D. Anderson study include: Gabriel Hortobagyi, M.D., Mien Chie Hung, Ph.D., Sharon Giordano, M.D., Funda Meric-Bernstam, M.D., Chad Barnett and Shu-Wan Kau.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Metformin Increases Pathologic Complete Response Rates In Breast Cancer Patients With Diabetes." ScienceDaily. ScienceDaily, 2 June 2008. <www.sciencedaily.com/releases/2008/06/080602132231.htm>.
University of Texas M. D. Anderson Cancer Center. (2008, June 2). Metformin Increases Pathologic Complete Response Rates In Breast Cancer Patients With Diabetes. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2008/06/080602132231.htm
University of Texas M. D. Anderson Cancer Center. "Metformin Increases Pathologic Complete Response Rates In Breast Cancer Patients With Diabetes." ScienceDaily. www.sciencedaily.com/releases/2008/06/080602132231.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins